Figure 3: Proportion of CD4+ T cells with a regulatory phenotype.
The percentage of T lymphocytes with a regulatory T-cell (Treg) phenotype was elevated following alemtuzumab treatment (12 mg; 2 annual courses of IV infusions) in treatment-naïve, relapsing-remitting MS patients (CARE-MS I; unpublished data). The proportion of Treg cells gradually returned toward baseline levels, but remained elevated at Month 12. (Data from Hartung et al. [42]).